Rosuvastatin dose
Searched over 200M research papers for "rosuvastatin dose"
Summary
10 papers analyzed
These studies suggest rosuvastatin is effective in reducing LDL cholesterol and improving lipid profiles at doses of 10 to 80 mg, with dose proportionality and good tolerability, and is more effective than equivalent doses of other statins like atorvastatin and simvastatin.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Rosuvastatin Dose: Pharmacokinetics, Efficacy, and Safety
Pharmacokinetics of Rosuvastatin
Rosuvastatin, a potent lipid-lowering agent, is administered once daily in doses ranging from 5 to 80 mg, with 40 mg being the maximum approved daily dose. The drug achieves its maximum plasma concentration approximately 5 hours after administration under fasting conditions. The mean absolute oral availability of rosuvastatin is about 20%, with a total clearance rate of 28.3 L/h and an elimination half-life of around 20 hours. Notably, there is significant variability in the pharmacokinetics of rosuvastatin among different races, with Caucasian subjects exhibiting a 1.7-fold higher clearance rate compared to Chinese subjects. Additionally, rosuvastatin shows a large coefficient of variation in systemic exposure (48%) and minor accumulation with repeated dosing.
Efficacy of Rosuvastatin in Lowering LDL-C
Rosuvastatin is highly effective in reducing low-density lipoprotein cholesterol (LDL-C). In dose-ranging studies, rosuvastatin demonstrated significant, dose-dependent reductions in LDL-C, with decreases ranging from 34% at 1 mg to 65% at 80 mg. The VOYAGER meta-analysis further confirmed that rosuvastatin doses of 5, 10, 20, and 40 mg reduced LDL-C by 39%, 44%, 50%, and 55%, respectively. These reductions were more substantial compared to equivalent doses of atorvastatin and simvastatin, with rosuvastatin showing 3 to 3.5 times higher potency than atorvastatin and 7 to 8 times higher potency than simvastatin.
Comparative Efficacy with Other Statins
In comparative studies, rosuvastatin consistently outperformed other statins in lowering LDL-C and achieving lipid goals. For instance, rosuvastatin 10 mg reduced LDL-C by 44.6%, significantly more than atorvastatin 20 mg, which reduced LDL-C by 42.7%. Similarly, the STELLAR trial demonstrated that rosuvastatin 10 to 80 mg reduced LDL-C by 8.2% more than atorvastatin, 26% more than pravastatin, and 12% to 18% more than simvastatin. These findings highlight rosuvastatin's superior efficacy in lipid management.
Safety and Tolerability
Rosuvastatin is generally well tolerated across various doses. In controlled trials, the adverse event profile of rosuvastatin 10 to 40 mg was similar to that of atorvastatin, simvastatin, and pravastatin. Myopathy occurred in less than 0.03% of patients, and no cases of rhabdomyolysis were reported at doses up to 40 mg. Additionally, clinically significant elevations in liver enzymes were rare, occurring in only 0.2% of patients. Even in patients with a history of statin intolerance, a once-a-week dosing regimen of rosuvastatin was well tolerated and led to significant lipid improvements.
Conclusion
Rosuvastatin is a highly effective and well-tolerated statin for lowering LDL-C and other atherogenic lipoproteins. Its pharmacokinetic profile, superior efficacy compared to other statins, and favorable safety profile make it a valuable option in the management of hypercholesterolemia and dyslipidemia.
Sources and full results
Most relevant research papers on this topic
